Product Data Sheet

Morroniside

Cat. No.: HY-N0532 CAS No.: 25406-64-8 Molecular Formula: $C_{17}H_{26}O_{11}$

Molecular Weight: 406.38

Target: MMP; Pyroptosis; Apoptosis

Pathway: Metabolic Enzyme/Protease; Apoptosis; Immunology/Inflammation

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (246.08 mM; Need ultrasonic) H₂O: 50 mg/mL (123.04 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 2.4608 mL | 12.3038 mL | 24.6075 mL |
| | 5 mM | 0.4922 mL | 2.4608 mL | 4.9215 mL |
| | 10 mM | 0.2461 mL | 1.2304 mL | 2.4608 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (246.08 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.12 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.12 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Morroniside has neuroprotective effect by inhibiting neuron apoptosis and MMP2/9 expression.

MMP2 MMP9 IC₅₀ & Target

In Vivo

Morroniside reduces the expression of MMP2 and MMP9 in an I/R injury model. Treatment with Morroniside significantly reduces I/R\u00edassociated neuron apoptosis in a dose dependent manner. The results demonstrate that active caspase\u00ed3 and Bax are significantly upregulated in the model group compared with the control group, while Bcl\u00ed2 is significantly downregulated. The expression of active caspase\u00ed3 and Bax is significantly downregulated by Morroniside treatment in a dose\u00eddependent manner, while the expression of Bcl\u00ed2 is significantly upregulated\u00ed1. Morroniside has an ameliorative effect on diabetes-induced alterations such as oxidative stress, inflammation, and apoptosis in the liver of type 2 diabetic db/db mice\u00ed2.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration [1]

Rats[1]

A total of 50 adult male Sprague Dawley rats (age, 7 8 weeks; weight, 260 280 g) are used. Rats are randomly assigned into five groups (n=10 in each). Rats in the control group undergo sham surgery. All other rats undergo suture occluded surgery, with a 0.26 mm nylon monofilament inserted through the right common carotid artery and are divided into groups as follows: The cerebral I/R injury model group (model), no treatment; low dose group, 30 mg/kg/day Morroniside by gavage; moderate dose group, 90 mg/kg/day Morroniside by gavage; high dose group, 270 mg/kg/day Morroniside by gavage. Rats in the control and model groups receive an equal volume of normal saline^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Zeng G, et al. Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting neuron apoptosis and MMP2/9 expression. Exp Ther Med. 2018 Sep;16(3):2229-2234.
- [2]. Park CH, et al. Evaluation of morroniside, iridoid glycoside from Corni Fructus, on diabetes-induced alterations such as oxidative stress, inflammation, and apoptosis in the liver of type 2 diabetic db/db mice. Biol Pharm Bull. 2011;34(10):1559-65.
- [3]. Huan Yu, et al. Morroniside attenuates apoptosis and pyroptosis of chondrocytes and ameliorates osteoarthritic development by inhibiting NF-кВ signaling. J Ethnopharmacol. 2021 Feb 10;266:113447.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA